HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

IsraelRecruitingPHASE1, PHASE2

Conditions

Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

St. Anna Kinderspital, Vienna, Austria
Contact: Study coordinator (Andishe Attarbaschi) · andishe.attarbaschi@stanna.at
Universitair Ziekenhuis Gent, Ghent, Belgium
Contact: Study coordinator (Barbara De Moerloose) · Barbara.DeMoerloose@uzgent.be
Rigshospitalet Copenhagen, Copenhagen, Denmark
Contact: Study coordinator (Ruta Tuckuviene) · ruta.tuckuviene@regionh.dk
Helsinki University Hospital, New Children's Hospital, Helsinki, Finland
Contact: Study coordinator (Antti Kyrönlahti) · antti.kyronlahti@hus.fi
Hôpital des Enfants GH Pellegrin - CHU de Bordeaux, Bordeaux, France
Contact: Study coordinator (Stephane Ducassou) · stephane.ducassou@chu-bordeaux.fr
CHRU Lille - Hôpital Jeanne de Flandre, Lille, France
Contact: Study coordinator (Bigitte Nelken) · brigitte.nelken@chu-lille.fr
Centre Léon Bérard, Lyon, France
Contact: Study coordinator (Nathalie Garnier) · nathalie.garnier@ihope.fr
Hopital La Timone - Enfants, Marseille, France
Contact: Study coordinator (Paul Saultier) · paul.saultier@ap-hm.fr
CHU Nantes Hôpital Mère-Enfant, Nantes, France
Contact: Study coordinator (Fanny Rialland) · fanny.rialland@chu-nantes.fr
Hôpital Robert Debré, Paris, France
Contact: Study coordinator (Marion Strullu) · marion.strullu@aphp.fr
Universitätsklinikum Augsburg, Augsburg, Germany
Contact: Study coordinator (Michael Frühwald) · Michael.Fruehwald@uk-augsburg.de
Charité Universitätsmedizin Berlin, Berlin, Germany
Contact: Study coordinator (Arend von Stackelberg) · arend.stackelberg@charite.de
Universitätsklinikum Essen, Essen, Germany
Contact: Study coordinator (Dirk Reinhardt) · dirk.reinhardt@uk-essen.de
Universitätsklinikum Frankfurt, Frankfurt, Germany
Contact: Study coordinator (Jan-Hemming Klusmann) · Jan-Henning.Klusmann@ukffm.de
Universitätsklinikum Münster, Münster, Germany
Contact: Study coordinator (Birgit Burkhardt) · birgit.burkhardt@ukmuenster.de
Our Lady's Hospital for Sick Children, Dublin, Ireland
Contact: Study coordinator (Andrea Malone) · andrea.malone@olchc.ie
Schneider's Children's Medical Center, Petah Tikva, Israel
Contact: Study coordinator (Gil Gilad) · gilgi@clalit.org.il
Sheba Medical Center Hospital, Ramat Gan, Israel
Contact: Study coordinator (Bella Bielorai) · bella.bielorai@sheba.health.gov.il
IRCCS Istituto Giannina Gaslini, Genova, Italy
Contact: Study coordinator (Concetta Micalizzi) · concettamicalizzi@gaslini.org
Fondazione MBBM c/o Centro ML Verga, Monza, Italy
Contact: Study coordinator (Carmelo Rizzari) · carmelo.rizzari@gmail.com
Padova Azienda Ospedaliera, Padova, Italy
Contact: Study coordinator (Marta Pillon) · marta.pillon@unipd.it
Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
Contact: Study coordinator (Franco Locatelli) · franco.locatelli@opbg.net
Ospedale Infantile Regina Margherita, Turin, Italy
Contact: Study coordinator (Franca Fagioli) · franca.fagioli@unito.it
Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, Netherlands
Contact: Study coordinator (Anne A.L Elsinghorst) · hem-ismart@prinsesmaximacentrum.nl
Oslo University Hospital, Oslo, Norway
Contact: Study coordinator (Jochen Büchner) · jocbuc@ous-hf.no
Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain
Contact: Study coordinator (Jose Luis Dapena Diaz) · joseluis.dapena@sjd.es
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Contact: Study coordinator (Alba Rubio San Simón) · alba.rubio@salud.madrid.org
La Fe, Valencia, Spain
Contact: Study coordinator (Carol Fuentes) · fuentes_car@gva.es
Karolinska university hospital, Stockholm, Sweden
Contact: Study coordinator (Anna Nilsson) · anna.nilsson.1@ki.se
Bristol Royal Hospital for Children, Bristol, United Kingdom
Contact: Study coordinator (Kristina Marshall) · kristina.marshall@uhbw.nhs.uk
Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Contact: Study coordinator (David O'Connor) · david.oconnor@gosh.nhs.uk
Great North Children's Hospital, Newcastle, United Kingdom
Contact: Study coordinator (Frederik van Delft) · Frederik.Van-Delft@newcastle.ac.uk
Royal Marsden NHS Trust, Sutton, United Kingdom
Contact: Study coordinator (Donna Lancaster) · donna.lancaster@rmh.nhs.uk

Study leads

Michel Zwaan, Prof. Dr.
Study Chair
Princess Máxima Center
Andrej Lissat, MD PhD
Principal Investigator
Charite University, Berlin, Germany

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma

Abroad (travel likely)RecruitingPHASE2

Charlotte, United States · Tulsa, United States

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma

Abroad (travel likely)Recruiting

Chicago, United States

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Brain and Central Nervous System Tumors · Chronic Myeloproliferative Disorders · Leukemia

Abroad (travel likely)Recruiting

Detroit, United States

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · T-lymphoblastic Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China